-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1766 Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) – an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)

Program: Oral and Poster Abstracts
Session: 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Research, CML, Chronic Myeloid Malignancies, Diseases, Therapy sequence, Treatment Considerations, Myeloid Malignancies
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Susanne Isfort1,2,3*, Kirsi Manz, PhD2,4,5,6*, Lino L. Teichmann, MD7,8*, Martina Crysandt, MD3,9*, Andreas Burchert, MD10, Andreas Hochhaus, MD11, Susanne Saussele, MD12, Alexander Kiani, MD13,14*, Joachim R. Goethert, MD15, Thomas Illmer, MD16*, Philippe Schafhausen17*, Haifa Kathrin Al-Ali18*, Frank Stegelmann, MD19*, Mathias Hänel, MD20, Tim Pfeiffer21*, Aristoteles Giagounidis, MD22, Georg-Nikolaus Franke, MD23*, Steffen Koschmieder, MD3,9, Alice Fabarius, PhD12*, Thomas Ernst, MD24, Mareille Warnken-Uhlich25*, Denise Kohn6*, Markus Pfirrmann, PhD6*, Dominik Wolf, M.D.7,8,26,27* and Tim H. H. Brummendorf, MD3,9,27

1Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany
2shared first authorship, Hannover, Germany
3Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, University Hospital RWTH Aachen, Aachen, Germany
4Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany
5Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, AL, Germany
6Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Ludwig-Maximilians-Universität, München, Germany
7Department of Medicine III, University Hospital Bonn, Bonn, Germany
8Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Bonn, Germany
9Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIOABCD), Aachen, Germany
10Department of Hematology, Oncology and Immunology, University Hospital Marburg, Marburg, Germany
11Hematology and Oncology, Comprehensive Cancer Center Central Germany – Campus Jena, Klinik für Innere Medizin II, Jena, Germany
12Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany
13Department of Hematology and Oncology, Klinikum Bayreuth, Bayreuth, Germany
14Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
15Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), University Hospital Essen, Essen, Germany
16Hematology Private Practice, Dresden, Germany
17Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
18Krukenberg Cancer Center Halle, Universitätsmedizin Halle, Halle (saale), Germany
19University Hospital of Ulm, Department of Internal Medicine III, Ulm, Germany
20Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany
21Department of Hematology and Oncology, Klinikum Augsburg, Augsburg, Germany
22Clinic for Hematology, Oncology and Palliative Care Marien Hospital Düsseldorf, Dusseldorf, Germany
23Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, University Leipzig Medical Center, Leipzig, Germany
24Jena University Hospital, Jena, Germany
25Clinical Study Core Unit Bonn, Institute of Clinical Chemistry and Clinical Pharmacology, University Bonn, Bonn, Germany
26University Hospital of Internal Medicine V (Hematology and Oncology), Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria
27Shared senior authorship, Bonn, Germany

Introduction: Currently, six tyrosine kinase inhibitors (TKIs) are approved for chronic phase chronic myeloid leukemia (CML). Unfortunately, treatment sequence has never been tested prospectively, and, therefore, it remains unclear which TKI should be chosen, especially after first-line treatment with more potent second generation (2G)-TKIs. The original goal of the “Bosutinib Dose Optimization Study” (BODO) study was to evaluate whether a bosutinib step-in dosing regimen decreases gastrointestinal (GI) toxicity while maintaining optimal efficacy in patients (pts) with CML after failure or intolerance to 2G-TKIs. Despite its premature study end, it thereby contains one of the largest cohorts of 2nd generation TKI treatment after failure/intolerance of a 2G-TKI in first line.

Methods: This is a sub-analysis of the BODO trial (NCT03205267), a multicenter, open-label single arm phase II study testing tolerability and efficacy of 2nd and 3rd line bosutinib step-in dosing in chronic phase CML pts intolerant and/or refractory to previous imatinib and/or nilotinib, and/or dasatinib therapy. Bosutinib was commenced with 300 mg QD and was (in the absence of > grade 1 toxicities) dose-increased by increments of 100 mg daily dosing every 14 days up to a maximum dose of 500 mg QD. 127 pts were planned to be recruited. However, due to slow recruitment, the trial had to be stopped prematurely after inclusion of 57 pts. For this analysis, we focused on the 45 patients treated with either nilotinib (n=23) or dasatinib (n=22) as first-line therapy. Cumulative incidence curves of response to bosutinib were calculated and compared using Gray’s test.

Results: 45 pts (n=28 males; median age 51 years, range: 19 - 77) were included in the analysis. The ECOG status was 0 (n=36, 80%) or 1 (n=9, 20%). Prior to study inclusion, a median daily dose of 600 mg nilotinib (range: 300 – 800) and 100 mg of dasatinib (range: 57 - 200) had been administered. The median duration of previous nilotinib and dasatinib therapy was 20.0 months (range: 23 days - 8.0 years) and 16.6 months (range: 3.7 - 34.3 months, p = 0.184), respectively. 18 (40%) pts were intolerant, 17 resistant (38%), and 10 (22%) both intolerant and resistant to previous TKI treatment.

17 (38%) pts entered the study in molecular response (at least major molecular remission (MMR) at screening). The odds of being in MMR at screening were higher in patients with longer pretreatment duration (OR = 1.9; CI: 1.1, 3.7; p = 0.038 per additional year of pretreatment). The corresponding probabilities of MMR were 40% (CI: 26, 54%), 58% (CI: 42, 71%), 68% (CI: 51, 80%) at 3, 6, and 12 months, and 79% (CI: 62, 89%) at 18 and 24 months, respectively. Median time to MMR was 4.9 months. MMR probabilities by pretreatment did not differ between nilotinib and dasatinib (p=0.788).

3 out of 4 intolerant pts without MMR at baseline reached MMR or a better molecular response level with bosutinib. 24 pts refractory to previous therapy (16 resistant; 8 both resistant and intolerant) were lacking baseline MMR, of which 16 pts achieved MMR or better (1 pt with MR4.5, 2 with MR4 and 13 with MMR). In the 24 refractory pts without MMR at baseline, the cumulative MMR and MR4 rates by 1 year were 48% (CI: 26, 68%) and 10% (CI: 2, 27%), respectively. One patient reached MR4.5 after 15.2 months of bosutinib therapy. Response to bosutinib was not significantly different in patients pretreated with either dasatinib or nilotinib. 33 pts received bosutinib for at least 6 months and also had a 6-months molecular response evaluation. At 6 months, median dose levels of bosutinib were not significantly different between responders and non-responders. No disease progressions were reported during the study and follow up.

All pts had ≥1 any grade treatment emergent adverse event (TEAE), occuring a median of 15 days after starting bosutinib (range: 1 - 225 days). Cumulative probability of grade 3/4 TEAEs, and serious adverse events by 1 year was 69% (53, 81%) and 26% (CI: 13, 40%), respectively. The most common TEAE was diarrhea with a cumulative probability of 63% (CI: 47, 76%) by 1 month.

Conclusion: Despite of the limitations of a single-arm study with incomplete recruitment, bosutinib was able to induce optimal responses in two thirds of pts previously resistant to 2G-TKIs while GI toxicity rarely led to treatment discontinuation. We conclude that bosutinib is a safe option after intolerance/failure of a 2G-TKI in first-line.

Disclosures: Isfort: Roche: Other: Travel support; Mundipharma: Other: Travel support; Silence Therapeutics: Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support; Incyte: Honoraria; GSK: Honoraria, Membership on an entity's Board of Directors or advisory committees; Alexion: Other: Travel support; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support; Hexal: Other: Travel support; AOP Orphan: Honoraria, Other: Travel support. Teichmann: AOP Pharma: Other; AOP Pharma, BMS, Jazz Pharmaceuticals, and Novartis: Honoraria; Blueprint Medicines, BMS, GSK, and Pfizer: Other: Advisory Board Honoraria. Crysandt: Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pierre Fabre: Honoraria; Jazz: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees. Hochhaus: Enliven: Honoraria, Other: Advisory Board; Terns: Honoraria, Other: Advisory Board; Novartis: Honoraria, Other: Advisory Board, Research Funding. Saussele: Novartis, BMS, Incyte: Research Funding; Novartis, Pfizer, Incyte, Roche: Honoraria. Goethert: Imago Biosciences: Consultancy; AOP Orphan Pharmaceuticals: Consultancy, Honoraria, Other: Travel support; BMS: Consultancy, Honoraria, Other: Travel support; Pfizer: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Other: Travel support; GSK: Consultancy, Honoraria; Blueprint Medicines: Consultancy, Honoraria; Pharma&: Honoraria; Incyte: Consultancy, Honoraria, Other: Travel support; porteros biostructures: Consultancy; CTI Biopharma: Consultancy; Abbvie: Consultancy. Al-Ali: AOP: Consultancy, Honoraria; MSD: Honoraria; Otsuka: Consultancy, Honoraria; Stemline: Honoraria; Blueprint: Consultancy, Honoraria; Alexion: Other: Travel grant; Blueprint: Honoraria; Abbvie: Consultancy, Honoraria, Other: Travel grant; BMS: Consultancy, Research Funding; GSK: Consultancy, Honoraria; Incyte: Research Funding; Novartis: Consultancy, Honoraria. Stegelmann: Abbvie: Consultancy, Honoraria, Speakers Bureau; BMS: Consultancy, Honoraria, Speakers Bureau; GSK: Consultancy, Honoraria, Speakers Bureau; Incyte: Consultancy, Honoraria, Speakers Bureau; MorphoSys: Consultancy, Honoraria, Speakers Bureau; Novartis: Consultancy, Honoraria, Speakers Bureau; Pfizer: Consultancy, Honoraria, Speakers Bureau. Hänel: Kite/Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead Sciences: Honoraria; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sobi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Falk Foundation: Honoraria; Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi-Aventis: Consultancy, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Consultancy, Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bayer Vital: Consultancy, Membership on an entity's Board of Directors or advisory committees; BristolMyersSquibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BristolMyersSquibb/Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria. Giagounidis: Amgen: Consultancy; BMS: Consultancy. Koschmieder: Novartis, BMS, Pfizer, Incyte, Ariad, Shire, Roche, AOP Pharma, Janssen, Geron, Celgene, Kartos, Abbvie, iOMEDICO, MSD: Honoraria; Pfizer, Incyte / Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Baxalta, Sanofi, MPN Hub, Protagonist, Sierra Oncology, Glaxo-Smith Kline, AbbVie, PharmaEssentia, MSD: Consultancy; Novartis Foundation, BMS, Novartis, AOP Pharma, Janssen/Geron: Research Funding; Alexion, Novartis, BMS, Incyte / Ariad, AOP Pharma, Baxalta, CTI, Pfizer, Sanofi, Celgene, Shire, Janssen, Geron, Kartos, Protagonist, Sierra Oncology, Glaxo-Smith Kline, Imago Biosciences, AbbVie, iOMEDICO, MSD: Speakers Bureau; RWTH Aachen University: Patents & Royalties: Patent filed on BET inhibitors; Member of EHA Guidelines Committee, Chairman Hemostasis Working Party of DGHO, Co-Speaker of German Study Group for MPN (GSG-MPN) and GSG-MPN bioregistry: Membership on an entity's Board of Directors or advisory committees. Brummendorf: Roche: Honoraria; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Ariad: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties: Combination of Imatinib with hypusination inhibitors, Research Funding; Merck: Honoraria; Repeat Dx: Consultancy, Research Funding; Gilead: Consultancy, Honoraria.

OffLabel Disclosure: Bosutinib is approved in Europe for patients with first-line CML-CP and for patients with CML-CP, -AP or -BP after pretreatment with at least one other TKI if Imatinib, Nilotinib or Dasatinib are not considered a feasible option. In our trial Bosutinib was used in second or third line treatment of CML-CP irrespectable of feasibility.

*signifies non-member of ASH